Journal article

Should hydroxyethyl starch be banned? - Authors' reply

Ian Roberts, Haleema Shakur, Rinaldo Bellomo, Julian Bion, Simon Finfer, Beverley Hunt, John Myburgh, Anders Perner, Konrad Reinhart


University of Melbourne Researchers


Funding Acknowledgements

JB was a member of the first advisory panel (PRAC) convened by the Medicines and Healthcare Products Regulatory Agency to advise the European Medicines Agency on the continued licensing of intravenous HES solutions. SF reports non-financial support from Baxter Healthcare, and financial support from Bristol-Myers Squibb, outside the submitted work. JM reports non-financial support from Baxter Healthcare and Fresenius Kabi, grants from CSL Bioplasma and National Health and Medical Research Council, and Fresenius Kabi, outside the submitted work. AP reports grants from CSL Behring, Ferring, and Fresenius Kabi, outside the submitted work. KR is a board member of the Global Sepsis Alliance, International Sepsis Forum, and Sepsis Foundation, and has received consultancy fees from Adrenomed and reimbursement from the International Sepsis Forum for participation in colloquia, and has stocks in InflaRx NV. All other authors declare no competing interests.